Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
McKesson
McKinsey
AstraZeneca
Express Scripts
Baxter

Last Updated: June 26, 2022

Bremelanotide acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for bremelanotide acetate and what is the scope of freedom to operate?

Bremelanotide acetate is the generic ingredient in one branded drug marketed by Palatin Technologies and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bremelanotide acetate has seventy-nine patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for bremelanotide acetate
International Patents:79
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:bremelanotide acetate at DailyMed
Anatomical Therapeutic Chemical (ATC) Classes for bremelanotide acetate

US Patents and Regulatory Information for bremelanotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bremelanotide acetate

Country Patent Number Title Estimated Expiration
Israel 159797 See Plans and Pricing
Australia 2005269831 See Plans and Pricing
Canada 2573142 See Plans and Pricing
Australia 2002322466 See Plans and Pricing
Spain 2235921 See Plans and Pricing
Mexico PA06013814 TERAPIA DE AGENTES MULTIPLES PARA LA DISFUNCION SEXUAL. (MULTIPLE AGENT THERAPY FOR SEXUAL DYSFUNCTION.) See Plans and Pricing
Japan 2008500369 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
Merck
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.